Stocktoria

Ovid Therapeutics Inc. OVID

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-05-05
Chart by TradingView
1/9
Piotroski F — financial health
0.8
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2025FY2024FY2024FY2024
Financials
Revenue$7.3M$223.6M$566,000$223.4M$223.2M
Operating income-$42.4M-$61.9M
Net income-$17.4M-$26.4M
Operating cash flow-$38.3M-$56.0M
Free cash flow-$38.3M-$56.0M
Total assets$150.9M$81.7M$92.2M$102.7M$118.1M
Total liabilities$20.3M$22.4M$23.9M$26.4M$29.2M
Shareholders' equity$130.7M$59.3M$68.2M$76.3M$88.9M
Ratios
Operating margin-585.2%-10933.7%
Net margin-240.1%-4670.1%
FCF margin-528.6%-9898.8%
Return on assets-11.5%-28.7%
Return on equity-13.3%-38.7%
Current ratio8.974.935.325.665.73
Revenue growth-96.8%39405.3%-99.7%0.1%0.1%

Notable holders (13F)

InvestorSharesValue
Point72 Asset Management, L.P.1,320,610$2.9M
RENAISSANCE TECHNOLOGIES LLC1,104,300$2.5M

Why these scores methodology →

Piotroski F-score: 1/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 0.8 (distress)

  • Working capital / assets 0.438
  • Retained earnings / assets -2.131
  • EBIT / assets -0.281
  • Equity / liabilities 6.445

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001636651 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.